tamoxifen and raloxifene for preventing breast cancer
July 1999
The National Cancer Institute is starting a HUGE study to compare tamoxifen and raloxifene for preventing breast cancer.
It's called STAR..."Study of Tamoxifen And Raloxifene."
Tamoxifen (Nolvadex) reduces the risk of breast cancer by almost 50% in high-risk women.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote